Multiple Myeloma (MM) Clinical Trial
Official title:
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
The purpose of this study is to see if researchers could get the same good results with less toxicity by using this new approach. We already know that the three drugs bortezomib, lenalidomide, and dexamethasone given together at the same time are effective. Most physicians therefore treat patients with multiple myeloma with the 3 drug combination. However, the researchers also know that the three drugs given together result in more side effects than when only 2 drugs (bortezomib and dexamethasone or lenalidomide and dexamethasone) are given. The researchers believe that all patients may not necessarily need the three drugs to have good results. In this study, the researchers will first treat your disease with bortezomib and dexamethasone. If the disease is not well controlled with these 2 drugs, only then the third drug, lenalidomide, will be added. By using this sequential approach we may reach the same good results with fewer side effects.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02265731 -
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05442580 -
CART-38 in Adult AML and MM Patients
|
Phase 1 | |
| Terminated |
NCT04178902 -
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02920697 -
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05908409 -
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04702425 -
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
|
Phase 1 | |
| Completed |
NCT00710528 -
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT04721002 -
Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
|
||
| Active, not recruiting |
NCT02240537 -
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02203643 -
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
|
Phase 2 | |
| Completed |
NCT02211014 -
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT04649073 -
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04123418 -
A Study of WVT078 in Patients With Multiple Myeloma (MM)
|
Phase 1 | |
| Recruiting |
NCT03018405 -
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
|
Phase 1/Phase 2 | |
| Terminated |
NCT01663766 -
Phase I Study of Milatuzumab for Graft Versus Host Disease
|
Phase 1 | |
| Withdrawn |
NCT05513612 -
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
|
Phase 1 | |
| Completed |
NCT01413568 -
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00889798 -
Tumor Registry of Lymphatic Neoplasia
|